- Home
- NUVL vs THO Comparison
NUVL vs THO Comparison
Compare NUVL & THO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NUVL
- THO
- Stock Information
- Founded
- NUVL 2017
- THO 1980
- Country
- NUVL United States
- THO United States
- Employees
- NUVL N/A
- THO N/A
- Industry
- NUVL Biotechnology: Pharmaceutical Preparations
- THO Homebuilding
- Sector
- NUVL Health Care
- THO Industrials
- Exchange
- NUVL Nasdaq
- THO Nasdaq
- Market Cap
- NUVL 5.5B
- THO 5.4B
- IPO Year
- NUVL 2021
- THO N/A
- Fundamental
- Price
- NUVL $79.49
- THO $99.01
- Analyst Decision
- NUVL Strong Buy
- THO Buy
- Analyst Count
- NUVL 11
- THO 6
- Target Price
- NUVL $112.36
- THO $111.80
- AVG Volume (30 Days)
- NUVL 420.4K
- THO 585.6K
- Earning Date
- NUVL 03-04-2025
- THO 03-05-2025
- Dividend Yield
- NUVL N/A
- THO 2.02%
- EPS Growth
- NUVL N/A
- THO N/A
- EPS
- NUVL N/A
- THO 3.93
- Revenue
- NUVL N/A
- THO $9,685,433,000.00
- Revenue This Year
- NUVL N/A
- THO N/A
- Revenue Next Year
- NUVL N/A
- THO $7.43
- P/E Ratio
- NUVL N/A
- THO $25.17
- Revenue Growth
- NUVL N/A
- THO N/A
- 52 Week Low
- NUVL $61.80
- THO $88.37
- 52 Week High
- NUVL $113.51
- THO $129.31
- Technical
- Relative Strength Index (RSI)
- NUVL 43.83
- THO 44.07
- Support Level
- NUVL $77.84
- THO $99.63
- Resistance Level
- NUVL $85.21
- THO $105.75
- Average True Range (ATR)
- NUVL 3.78
- THO 2.78
- MACD
- NUVL -0.46
- THO -0.26
- Stochastic Oscillator
- NUVL 12.08
- THO 23.50
About NUVL Nuvalent Inc.
Nuvalent Inc is a clinical stage biopharmaceutical company focused on creating precisely targeted therapies for patients with cancer. All of the Company's operations are in the United States. The company is engaged in developing small molecules that are designed to overcome the limitations of existing therapies for clinically proven kinase targets. The product candidates of the company include NVL-520, which is being developed for patients with ROS1-positive non-small cell lung cancer (NSCLC), NVL-655, which is being developed for patients with anaplastic lymphoma kinase (ALK)-positive NSCLC, NVL-330, is a brain-penetrant human epidermal growth factor receptor 2 (HER2)-selective inhibitor designed to address the combined medical need of treating tumors driven by HER2ex20.
About THO Thor Industries Inc.
Based in Elkhart, Indiana, Thor Industries manufactures Class A, Class B, and Class C motor homes along with travel trailers and fifth wheel towables across over 30 brands. Through the acquisition of Erwin Hymer in 2019, the company expanded its geographic footprint and now produces various motorized and towable recreational vehicles for Europe, including motorcaravans, campervans, urban vehicles, caravans, and other RV-related products and services. The company has also begun generating revenue through aftermarket component parts through the acquisition of Airxcel in 2021, however, this is still a nascent part of the business as it accounts for less than 10% of total sales. In fiscal 2023, the company wholesaled 187,015 units and generated over $11.1 billion in revenue.